Corporate Communications
Week ending August 16, 2026
1. This week’s narrative in one paragraph
AI assistants are generally describing Cosentyx as a credible, established biologic whose choice depends on patient fit rather than being universally “stronger” or “best.” Answers repeatedly emphasize its IL-17A mechanism, comparisons with Taltz, Humira, Stelara and Enbrel, practical dosing, and shared decision-making. The clearest positive framing is that it may be “more targeted,” “highly effective,” and relatively convenient because maintenance dosing is less frequent. At the same time, answers routinely raise infection, candidiasis, inflammatory bowel disease, pregnancy, and vaccine considerations. The narrative is broadly balanced, but not consistently precise: some answers use competitive language such as “best,” “superior,” or “stronger,” while others explicitly advise against those comparisons.
2. Anything with public-story potential
-
Boxed-warning contradiction — highest public-story potential. In response variants to the safety question, five say Cosentyx has no U.S. boxed warning, while one says it has one boxed warning for serious infections. The public story would be: “AI assistants give conflicting answers about whether Cosentyx carries a boxed warning.” This is a Corp Comms trust and misinformation issue, separate from the underlying safety assessment.
-
Inconsistent pregnancy and treatment-restriction framing. Responses to pregnancy/lactation questions vary between “limited data,” “not recommended unless benefit justifies risk,” and “do not use.” The likely story would be: “AI gives pregnant patients different answers about whether Cosentyx is appropriate and what precautions apply.” This is especially sensitive because the question also concerns infants and live vaccines.
-
Conflicting dosing instructions. In six answers about plaque-psoriasis dosing, some describe four weekly loading doses (weeks 0–3), while others describe five (weeks 0–4). The public story would be: “Patients asking AI how to take Cosentyx receive different injection schedules.” This is primarily a Medical/PV issue, but it becomes a communications risk if screenshots circulate.
3. Topics with a public-attention history
Biosimilar/generic substitution remains visible in nine responses, including one statement that Cosentyx is “commonly treated as interchangeable with approved biosimilars.” The topic is down from 13 last week, so there is no new escalation, but access and substitution questions remain a credible patient-advocacy or pharmacy story. Switching answers also repeatedly mention insurance and prior authorization. Off-label language appears only once, down from three; there is no compounding signal in the supplied data.
4. Trajectory
Overall exposure is stable to modestly improving, with inconsistency flags declining from 28 to 24 over the available weeks and most category counts falling from last week. However, contraindication language remains at 27, unchanged from last week, and the boxed-warning contradiction persists as a recurring high-concern issue. Competitor mentions have also declined, with Taltz still the most common.
5. Recommended actions
- Prepare a short holding statement on the boxed-warning contradiction, pending confirmation of the current approved U.S. labeling; this is the most readily screenshot-able issue.
- Coordinate with Medical Affairs/PV on a single public-facing explanation of safety terminology, including boxed warning, infection risk, IBD, pregnancy, and vaccine language.
- Ask Medical Affairs to review the dosing inconsistency and device descriptions; Comms should be ready with a neutral redirect to current prescribing information, not clinical advice.
- Monitor biosimilar substitution and access framing only this week; both are down, but remain historically sensitive topics.